Educational Symposium
The Role of Hemodiafiltration in the Management of Dialysis-Dependent Chronic Kidney Failure
October 25, 2024 | 12:45 PM - 01:45 PM
Location: Marriott Grand Ballroom 4, Marriott Marquis
Session Description
There has been increasing recognition of hemodiafiltration (HDF) for the management of patients with dialysis-dependent chronic kidney failure. HDF employs increased convection in combination with diffusion in an effort to enhance the removal of large solutes such as beta-2 microglobulin and kappa and lambda light chains. Prior randomized controlled trials comparing HDF to conventional hemodialysis showed conflicting results in terms of survival benefit and reduction in plasma levels of large solutes. Of particular interest is a recent randomized controlled trial of HDF employing higher convection volumes which demonstrated survival benefit.This symposium reviews the technological aspects and considerations that are required to provide HDF therapy. Data from HDF trials investigating quality of life and mortality in patients with dialysis-dependent chronic kidney failure will also be discussed.
Support is provided by an educational grant from Fresenius Medical Care Renal Therapies Group LLC.
Learning Objective(s)
- Discuss the technological considerations (e.g., replacement fluid, dialyzer membrane, machine) required to provide HDF therapy
- Describe data from the trials investigating the effect of HDF on outcomes in patients with dialysis-dependent chronic kidney failure
Learning Pathway(s)
- Dialysis
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- The Technological Aspects of HDF
12:55 PM - 01:15 PM
- Effect of HDF on the Quality of Life and Mortality of Patients: A Review of the Randomized Clinical Trials
01:15 PM - 01:35 PM
- Audience Q&A
01:35 PM - 01:45 PM